November 2026

Executive summary

1 confirmed change released, 24 products showing source movement, 2 evidence limits lifted

• MARKET OBSERVATIONFormulaSignal released 1 confirmed change in November 2026, across 1 brand: JYM Supplement Science. It rests on two dated states and was reviewed.
• MARKET OBSERVATIONMonitoring ran on 7 days in this period and recorded source movement on 24 of 340 products whose sources were answering. Movement routes to review; none of it is reported here as a change.
• RECORD DEVELOPMENT2 recorded evidence limits lifted this period, which means new evidence became available on a dimension the Record had recorded as unobservable. That is FormulaSignal learning more, not the market moving.
• MARKET OBSERVATIONAmong the 128 products whose current label lets caffeine be computed line by line, the median is 250 mg and the range runs 100 mg to 450 mg. 61 sit under 250 mg and 58 sit at 300 mg or above, with 9 between them.
• MARKET OBSERVATIONPrice per serving across the 225 products where the arithmetic describes one package runs $0.40 to $3.75, with a median of $1.50 and the middle half between $1.10 and $2.00. Every one is an observed price, and none of them records a list basis.
• MARKET OBSERVATIONAcross the 177 products disclosing an amount for every line, beta-alanine appears on 132 and creatine on 42. In this cohort a product not declaring an ingredient is established rather than assumed, because every line on those panels carries an amount.
• RECORD DEVELOPMENTFigures in this edition describe 359 covered products across 87 brands, read as of November 7, 2026. Coverage is a defined set, not a census of the category, and 205 products carry at least one recorded limit on what can currently be observed.

A market observation describes something the Record observed about a product or its commercial context. A record development describes a change in FormulaSignal’s own evidence. A figure that moved between editions for the second reason is not a category event.

What changed

A confirmed change enters an edition on the date FormulaSignal released it, not on the date the underlying states were observed. Both dates are printed on every entry.

Readings

Each reading names the fact under it, the benchmark that gives the fact meaning, and the interpretation that follows. A possible implication is stated as a possibility, because FormulaSignal observes the Record and does not forecast a market.

2 further readings are in the full edition.

Limitations

• Every figure describes 359 covered products across 87 brands. FormulaSignal does not claim to observe every product sold in the category, and nothing here is a market share, a sales figure or a shipment estimate.
• 182 of 359 products do not disclose an amount for every line on their current panel, through a proprietary blend, a line stating no amount, or no current first-party panel at all. Ingredient counts in this edition run over the 177 that do, because that is the only set where a product not declaring an ingredient means anything.
• No covered product's newest price observation records whether it was a list or a promotional price. Every price in this edition is an observed price on a stated date. No percentage price change is published, and nothing here is called a list price.
• 2 products are excluded from price per serving because the container holds one serving, so an observed package price does not establish whether it covered one unit or a case.
• Historical depth is uneven. 26 of 359 products hold an earlier state the Record will compare against the panel on file today. FormulaSignal holds dated states, never a continuous log, and infers nothing about the gap between two of them.
• An observation date is the date FormulaSignal read a source. It is not a manufacture date, a rollout date, or the date a product actually changed.
• 123 candidates are awaiting review. None of them appears in this edition in any form, because an unreviewed candidate is not a finding.

Corrections

A correction to a finding travels with the finding. A frozen edition is never rewritten: the correction record is published beside the finding it touches, so a reader can tell what an earlier edition said from what the Record holds now.

• AMENDED Axe & Sledge DBAP, accepted November 4, 2026. The page labeled October 31 as both reviewed and released beside a newer source observed November 1.. The stored review is a date-only October 31 entry. Both panel-reading records are dated November 1. The evidence was committed November 1 at 01:29:41 UTC; that is not a recorded publication or review time. The original review time zone is absent, so the exact sequence cannot be established. The declared label comparison stands; the claim to an independently established October 31 release date does not..
• AMENDED 1st Phorm Megawatt, accepted October 21, 2026. The tub went from about 50 servings to about 40 at the same 5.5 g scoop, so a tub holds about 20% fewer servings. Both Pink Lemonade panels print a 5.5 g scoop and approximate servings (about 50, about 40). Neither shows a net weight, so they may be one tub that shrank or two tub sizes.
• AMENDED Cellucor C4 Original, accepted August 3, 2026. List price $29.99 to $34.99 on the homepage signal card, with observed standard price and price per serving increased 16.7% as commercial context. Both endpoint offer observations for 2024-01-25 and 2024-02-26 carry price_basis UNKNOWN. The record does not establish that either archived price was a list price rather than a promotional one, so neither the List price label nor a percentage move between them was supported..
• AMENDED Beyond Raw LIT V2 Pre-Workout, accepted July 29, 2026. The V1 to V2 change window ended 2025-09-12. Neither endpoint capture was observed on 2025-09-12. The captures on file were observed 2025-08-01 and 2026-07-23, so the stated window end was a rollout date from secondary coverage rather than an observation.